Zhao Xuefei, Xia Hanting, Yang Yiwen, Ma Tianyou, Lu Yichen, Xie Zhefei, Zhou Xing, Liu Jiangyuan, Bao Zhengsheng, Xu Huihui, Ma Jinjin, Ling Houfu, Zhang Shuyan, Xu Taotao, Tong Peijian, Jin Hongting
Institute of Orthopaedics and Traumatology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310006, China.
The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
J Orthop Translat. 2025 Jul 2;53:246-259. doi: 10.1016/j.jot.2025.05.006. eCollection 2025 Jul.
BACKGROUND/OBJECTIVE: Cartilage defects (CDs) present a significant challenge in orthopaedic medicine. Owing to the inherently limited regenerative capacity of cartilaginous tissue, defects usually do not heal via natural repair processes. Consequently, damaged tissue is replaced by fibrocartilage-like tissues instead of the original hyaline cartilage. Therefore, inhibiting fibrocartilage formation while promoting hyalinisation may represent a novel strategy for CD therapy. Although studies have explored the role of interleukin (IL)-17A and ferroptosis in the fibrosis of visceral organs, such as the liver, lungs, and kidneys, their implication in cartilage fibrosis and fibrocartilage formation remains unclear. Herein, we aimed to determine whether IL-17A and ferroptosis are collectively involved in the process of cartilage fibrosis and to investigate the effects of amygdalin (AMD) and magnesium ions (Mg) in cartilage regeneration and the potential molecular mechanisms underlying these effects.
Cartilage samples were collected from patients with osteoarthritis and subjected to immunohistochemistry analysis to assess fibrocartilage formation indicators within the degenerated areas. Quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry analyses were employed to assess changes in cartilage anabolism and expression of fibrocartilage markers after treatment with different concentrations of AMD. We also treated chondrocytes with an IL-17A/RA antagonist, a ferroptosis inhibitor, a ferroptosis inducer, and AMD, and measured the changes in fibrocartilage-, ferroptosis-, and IL-17 signalling-associated factors. Finally, mice with microfracture (MF)-induced CDs were administered intra-articular injections of either saline, AMD (10 μmol/L), MgCl (0.5 mmol/L), or AMD (10 μmol/mL) plus MgCl (0.5 mmol/L) twice a week. After 4 and 8 weeks, chondral repair was assessed through histological and immunohistochemical analyses in each group.
IL-17A activated lipid peroxidation, leading to chondrocyte ferroptosis, while AMD suppressed IL-17 signalling, thereby mitigating the decrease in glutathione peroxidase 4 (GPX4) expression induced by IL-17A or erastin. In mice with MF surgery-induced CD, the combination of AMD and Mg mitigated oxidative stress, thereby enhancing the positive effects of Mg. This combination led to a significant improvement in chondrogenesis, activation of anabolic processes, and reduction of catabolic activity in the articular cartilage, ultimately supporting cartilage repair and regeneration.
AMD targets IL-17 signalling to inhibit chondrocyte ferroptosis. Furthermore, the combination of AMD and Mg suppresses IL-17A/GPX4 signalling, suppressing fibrocartilage formation and fostering hyaline cartilage regeneration.
In the present study, we showed that IL-17A may represent a promising therapeutic target for cartilage repair and regeneration. A conservative therapeutic strategy involving joint injections of AMD (a natural plant extract) and Mg (a crucial endogenous factor that promotes chondrogenesis) facilitated effective cartilage repair and regeneration. This strategy represents a cost-effective approach with potential for clinical application.
背景/目的:软骨缺损(CDs)是骨医学面临的重大挑战。由于软骨组织固有的再生能力有限,缺损通常无法通过自然修复过程愈合。因此,受损组织被纤维软骨样组织取代,而非原始的透明软骨。所以,抑制纤维软骨形成并促进透明化可能是一种治疗CD的新策略。尽管已有研究探讨白细胞介素(IL)-17A和铁死亡在内脏器官(如肝脏、肺和肾脏)纤维化中的作用,但其在软骨纤维化和纤维软骨形成中的意义仍不明确。在此,我们旨在确定IL-17A和铁死亡是否共同参与软骨纤维化过程,并研究苦杏仁苷(AMD)和镁离子(Mg)在软骨再生中的作用及其潜在分子机制。
收集骨关节炎患者的软骨样本,进行免疫组织化学分析,以评估退变区域内的纤维软骨形成指标。采用定量实时聚合酶链反应、蛋白质印迹和免疫组织化学分析,评估不同浓度AMD处理后软骨合成代谢的变化以及纤维软骨标志物的表达。我们还用IL-17A/RA拮抗剂、铁死亡抑制剂和诱导剂以及AMD处理软骨细胞,并检测纤维软骨、铁死亡和IL-17信号相关因子的变化。最后,对微骨折(MF)诱导的CD小鼠每周两次关节内注射生理盐水、AMD(10 μmol/L)、MgCl₂(0.5 mmol/L)或AMD(10 μmol/mL)加MgCl₂(0.5 mmol/L)。4周和8周后,通过组织学和免疫组织化学分析评估每组的软骨修复情况。
IL-17A激活脂质过氧化,导致软骨细胞铁死亡,而AMD抑制IL-17信号,从而减轻IL-17A或埃拉斯汀诱导的谷胱甘肽过氧化物酶4(GPX4)表达降低。在MF手术诱导的CD小鼠中,AMD和Mg的联合使用减轻了氧化应激,从而增强了Mg的积极作用。这种联合显著改善了软骨生成,激活了合成代谢过程,降低了关节软骨的分解代谢活性,最终促进了软骨修复和再生。
AMD靶向IL-17信号以抑制软骨细胞铁死亡。此外,AMD和Mg的联合抑制IL-17A/GPX4信号,抑制纤维软骨形成,促进透明软骨再生。
在本研究中,我们表明IL-17A可能是软骨修复和再生的一个有前景的治疗靶点。一种保守的治疗策略,即关节注射AMD(一种天然植物提取物)和Mg(一种促进软骨生成的关键内源性因子),促进了有效的软骨修复和再生。这种策略是一种具有临床应用潜力的经济有效的方法。